SAM
CRNX icon

SEB Asset Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

SEB Asset Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8M Hold
213,891
– – 0.03% 376
2026
Q1 		$7.77M Buy
+213,891
New +$9.55M 0.03% 364

Other funds holding CRNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

SEB Asset Management's CRNX Position: Q2 2026 in Review

SEB Asset Management held its Crinetics Pharmaceuticals (CRNX) position steady in Q2 2026 at 213,891 shares worth $8M. The position accounts for 0.03% of the portfolio, ranked #376.

SEB Asset Management first reported a position in CRNX in Q1 2026 and has held it in 2 quarters since. 250 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • SEB Asset Management held 213,891 shares of Crinetics Pharmaceuticals worth $8M as of Q2 2026.
  • SEB Asset Management left its Crinetics Pharmaceuticals share count unchanged in Q2 2026.
  • Crinetics Pharmaceuticals made up 0.03% of SEB Asset Management's portfolio in Q2 2026, its #376 holding.
  • SEB Asset Management first reported a position in Crinetics Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 250 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on SEB Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.